{"ticker": {"uuid": "3a7ae75a-339e-46b3-9acf-f0ebc63b0ca8", "symbol": "XRTX", "name": "XORTX Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "XORTX Therapeutics (XRTX) Investor presentation Summary", "summary": "This article summarizes an investor presentation by XORTX Therapeutics (XRTX), highlighting its drug candidates XRx-026 for gout and XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XRx-026 targets a significant market opportunity with NDA submission planned for ", "url": "https://quartr.com/events/xortx-therapeutics-inc-xrtx-investor-presentation_F6YbmTrE", "source_name": "Quartr", "published_at": "2026-07-20T16:41:35", "published_display": "20 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Q4 2024 earnings summary", "summary": "XORTX Therapeutics (XRTX) reported an unqualified audit opinion for 2024, but with material uncertainty regarding its ability to continue as a going concern due to recurring operating losses and the need for additional financing. The company's cash decreased to $2.47M, and it rep", "url": "https://quartr.com/events/xortx-therapeutics-xrtx-q4-2024_F6YbyXRI", "source_name": "Quartr", "published_at": "2026-07-20T16:41:35", "published_display": "20 Jul 2026 16:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of XORTX Therapeutics, Inc. \u2013 LSX:A427MJ", "summary": "This article focuses on the \"Price to earnings forward\" financial metric for XORTX Therapeutics, Inc. (A427MJ) listed on the Lang & Schwarz Exchange, according to TradingView. The content provided is minimal, indicating no trades and a closed market. It also highlights the origin", "url": "https://www.tradingview.com/symbols/LSX-A427MJ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T19:10:04", "published_display": "13 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains Momentum - Money Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUVNPaUExZmtlN09GWlp1R0hLdGhWQktHR2hmN0N4RXYzX0ZiTUJQdURJcVRaZnpXeXJ4TFptNXhNclFnRHgtWE5KSHBHYUE0c2NockQ2TTlIZGtqbUpzUmhVZ3ZnNXhQRTJKeFJsdTdGXzhpeGFqUGpSYko3TUxPUmU0VUZVc054UUVVbTR1blZxOUp5NHFZMTFyMDl4UTI3ZjZUZmtJc2hEU2tTaVZsMDNn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T22:41:04+00:00", "published_display": "12 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum Builds - Descending Triangle", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNcmNUd0d6VUV1TWVETVlGQkw1ZGt2TlpKRXJzRzlMUndiRGk0a2JPRjQ3c085Q2E0V3AxM0M5dWR4VDJ0bUJHUkVSZUljaFh5NkFLVW1aMENxWGwybjZhZjlEX0RaaG1iSDB4aWVXN09FSzNhU29BZFFteTIzNWpqT1ZOU0ZrSGFPUFJjbHk4eGdteXQwYWhlVmJDanNhUEhRdjU3ODhB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T22:38:27+00:00", "published_display": "12 Jul 2026 22:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for XORTX Therapeutics Inc. (XRTX) stock. It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also includes general trading information an", "url": "https://timothysykes.com/quote/XRTX/", "source_name": "timothysykes.com", "published_at": "2026-07-09T10:39:56", "published_display": "09 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xortx Therapeutics updates investors on kidney disease focus", "summary": "Xortx Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for progressive kidney disease and conditions associated with elevated uric acid. The company's strategy centers on long-term growth through clinical development milestones rather tha", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xortx-therapeutics-updates-investors-on-kidney-disease-focus/69716072", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:53", "published_display": "07 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of XORTX Therapeutics, Inc. \u2013 TSXV:XRTX", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for XORTX Therapeutics, Inc. (TSXV:XRTX). It is a financial data page from TradingView, displaying stock information for XORTX Therapeutics within the Health Technology and Pharmaceuticals sector on the TSX Ven", "url": "https://www.tradingview.com/symbols/TSXV-XRTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T23:12:13", "published_display": "05 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News", "summary": "This article provides access to the stock options chain, quotes, and news for XORTX Therapeutics (XRTX). It serves as a financial data portal for investors interested in the company's stock performance and related market activities.", "url": "https://www.moomoo.com/stock/XRTX-US/options-chain?chain_id=Name1K9-3FXPhg.1kvafk0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FSOFI-US%2Ffinancials-key-indicators%22%7D", "source_name": "Moomoo", "published_at": "2026-07-05T21:41:33", "published_display": "05 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of XORTX Therapeutics, Inc. \u2013 TSXV:XRTX", "summary": "The article discusses the forward price-to-sales ratio for XORTX Therapeutics, Inc. (TSXV:XRTX). It also mentions that the stock market for XRTX is currently closed with no trades. The majority of the content consists of navigation links and policy information for the TradingView", "url": "https://www.tradingview.com/symbols/TSXV-XRTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T04:10:41", "published_display": "05 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of XORTX Therapeutics Inc (XRTX) focusing on its financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. However, it notes that key financial data such as total revenue, operating profit, and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:49", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for XORTX Therapeutics Inc (XRTX), detailing its current stock price, market cap, and daily performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet. The content i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:44", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "XORTX Therapeutics Inc (XRTX) has a \"Buy\" trend rating based on one analyst's assessment, with a target price of USD 14.00, representing a significant upside potential of +2943.48%. The article provides an overview of earnings forecasts, analyst ratings, and peer comparisons for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:13", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Institutional Confidence", "summary": "This article provides details on XORTX Therapeutics Inc (XRTX)'s institutional confidence, including its current stock price, market capitalization, and changes in institutional shareholdings. Several institutional investors and individuals are listed with their shareholdings and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:13", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of XORTX Therapeutics Inc (XRTX) including its current stock price, market capitalization, and historical dividend and stock split information. It notes that the company has not distributed any dividends in the past five years but has undergone s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:29", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides details on XORTX Therapeutics Inc (XRTX), including its market capitalization and recent stock performance. It notes that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also serves as a gene", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:29", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]", "summary": "This document is a 6-K report filed by XORTX Therapeutics, indicating it is a report of a foreign private issuer under the Securities Exchange Act. The content consists solely of the word \"Document,\" suggesting it is a placeholder or a link to a separate document.", "url": "https://www.moomoo.com/news/notice/307528807/xortx-therapeutics-6-k-report-of-foreign-private-issuer-rules", "source_name": "Moomoo", "published_at": "2026-06-16T02:39:44", "published_display": "16 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-therapeutics-appoints-mika-grasso-132347043.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:23:47+00:00", "published_display": "15 Jun 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xortx Therapeutics Appoints Mika Grasso as Co-CEO; Provides Gout Drug Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-therapeutics-appoints-mika-grasso-131555980.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:15:55+00:00", "published_display": "15 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A 28-year-old co-CEO and XORTX's $700M gout push in the US", "summary": "XORTX Therapeutics has appointed Mika Grasso, 28, as co-CEO to oversee finance and public markets, coinciding with a corporate update detailing its strategic path for gout and kidney disease programs. The company is preparing an IND and planning a 505(b)(2) NDA submission for its", "url": "https://www.stocktitan.net/news/XRTX/xortx-provides-corporate-update-and-announces-appointment-of-mika-h6v6rkezpseq.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:40:14", "published_display": "15 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO", "summary": "XORTX Therapeutics is strategically refocusing on its lead gout drug candidate, XRx-026, and expanding its leadership team with the appointment of Mika Grasso as co-CEO for finance and public markets. The company plans to submit an IND and an NDA via the 505(b)(2) pathway, suppor", "url": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-3e4b6793b7b2.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:40:14", "published_display": "15 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO", "summary": "XORTX Therapeutics Inc. has provided a corporate update, refocusing on drug development programs and regulatory filings for its lead gout treatment, XRx-026. The company announced the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets, and is advanci", "url": "https://www.globenewswire.com/news-release/2026/06/15/3311671/0/en/xortx-provides-corporate-update-and-announces-appointment-of-mika-grasso-as-co-ceo.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing", "summary": "XORTX Therapeutics Inc. (TSE:XRTX) announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs, administrative burdens, and regulatory complexities. The company will maintain its Nasdaq listing, ensuring all shareholders can contin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XRTX-Q/pressreleases/2458260/xortx-to-voluntarily-delist-from-tsx-venture-exchange-maintain-nasdaq-listing/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T13:40:00", "published_display": "14 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange", "summary": "XORTX Therapeutics Inc. (NASDAQ: XRTX) has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs, optimize financing initiatives, and minimize regulatory complexity. The company determined that maintaining a dual listing was ", "url": "https://www.globenewswire.com/news-release/2026/06/12/3311334/0/en/xortx-announces-election-to-voluntary-delist-from-the-tsx-venture-exchange.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T12:10:19", "published_display": "13 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture", "summary": "XORTX Therapeutics has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs and administrative burdens associated with a dual listing. The company will maintain its listing on Nasdaq, where all shareholders will continue to ", "url": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-0e10adbeb0c3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:33", "published_display": "12 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX drops TSX Venture listing to reduce costs, focus on gout drug", "summary": "XORTX Therapeutics Inc. (NASDAQ:XRTX) has voluntarily decided to delist its common shares from the TSX Venture Exchange to reduce costs and streamline operations, according to a strategic review. The move is expected to cut exchange, legal, and accounting fees, optimize financing", "url": "https://www.stocktitan.net/news/XRTX/xortx-announces-election-to-voluntary-delist-from-the-tsx-venture-rsh5in5mrkqx.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:33", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XRTX - XORTX Therapeutics Inc Stock Price and Quote", "summary": "This article provides detailed stock information for XORTX Therapeutics Inc (XRTX), including its latest closing price, financial metrics, insider ownership, performance over various periods, and recent news releases. It covers aspects like market capitalization, sales, earnings ", "url": "https://finviz.com/stock?t=XRTX", "source_name": "Finviz", "published_at": "2026-06-03T20:40:07", "published_display": "03 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Edges Higher as Stock Holds Above Key Support - Schiff Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNeUJidHIzQ285TXBMOGdSUUdESWNiaE1EQlRaTGxITWdpSnhDNmtyaE1teFRsdndyYjF1UWcteWUzcVVudFNtMTUzelVDcU4weEJyZmw5MTNRSnBwM1Z2Vmdya3hydFQ1MUNwR1NjNUZmMHhJOE9iQXdYR0laQkdzNG5CNlNaUHFJMmFzMnRfS0RoMHpUUHU1VzNha0dWcHhTd1NPdXJjengtY3FMOERpLS1LWQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading Session - Factor Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUzEtQ25CaGNTQ0lqWEp0eFFaZ3QzQURmc0VqejlraEdyWjJicXI3eUU3WUI0UkdWN0ZKVnJvMG1HcG45bHlwTVBmcEVUblpsZlI3VjBiVDVycHZZV045dk0wdGJLanNJbzAxMTNGbGJDajhrN0FrOUhwQzZralRKWXYyOHhWc2hLTjNmbEh6M3RQX3N5dGpzTWpGeUV1bHlxRVNGRFB3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Gains 1.27% as Shares Test Key Resistance Level - Overnight Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQUGp6NHB4SFM4cGVId3JKZ3RHVHpsR1B3TXplWDFaZ2czaGIzNUZYZENKWEtwT2pTb1BIaS05VWxTV1kwQ25CM1JkVGd5N3pjaV9OZmNFOWpBQ0xJMlBIX2tkVUZTUk5VTVdzYUQ4T1dCb2tjbEhQMDdHeWRiLTI3YU01alB0NVE5TEYyWHNNaVA2dU55dG9nX0p4Q0VEcmRXN1EzMG00RkdtZnpqcXFtWklYZFg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XRTX News | XORTX THERAPEUTICS INC (NASDAQ:XRTX)", "summary": "This article provides recent news and stock information for XORTX Therapeutics Inc. (NASDAQ: XRTX). It highlights the current stock price, after-hours trading, and recent press releases, including the closing and announcement of a US$5 million public offering.", "url": "https://www.chartmill.com/stock/quote/XRTX/news", "source_name": "ChartMill", "published_at": "2026-05-27T05:09:24", "published_display": "27 May 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Company Profile & Introduction", "summary": "This entry serves as a company profile and introduction for XORTX Therapeutics.", "url": "https://www.moomoo.com/stock/XRTX-US/company?chain_id=Name1K9-3FXPhg.1l0a440&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FNWLFF-US%2Ffinancials-income-statement%22%7D", "source_name": "Moomoo", "published_at": "2026-05-22T16:39:07", "published_display": "22 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Announces Closing of US$5 Million Public Offering", "summary": "XORTX Therapeutics Inc. has closed a public offering of common shares and pre-funded warrants, raising US$5 million. The company plans to use the net proceeds for working capital, general corporate purposes, and investor relations activities, including a US$2.5 million payment to", "url": "https://www.globenewswire.com/news-release/2026/05/19/3297319/0/en/xortx-announces-closing-of-us-5-million-public-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T01:39:57", "published_display": "20 May 2026 01:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Raises US$5 Million Via Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-therapeutics-raises-us-5-121501672.html", "source_name": "MT Newswires", "published_at": "2026-05-19T12:15:01+00:00", "published_display": "19 May 2026 12:15", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/e-f-hutton-co-serves-152000474.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T15:20:00+00:00", "published_display": "18 May 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9%", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/xortx-therapeutics-raising-us-5-181709580.html", "source_name": "MT Newswires", "published_at": "2026-05-14T18:17:09+00:00", "published_display": "14 May 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Announces US$5 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-announces-us-5-million-110000771.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:00:00+00:00", "published_display": "14 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XORTX Meets Nasdaq Continued Listing Requirements", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQajJ3U21JU2xCbUNjZVhla20yeVZ2S0xMSF9aX1F3WWtSWmltZWw4ZEd6OFJ1OTBSTXB2blVwcEFXSUxQMUFEYUdtMW5sN084UU9OTDNBN1BUYW9mc0lpV1R3VjRwQWpKZF9jZk1tS1d4dWJpb3FpM3hkVU00Ni1wcW1iSlBNVG5wRUFKOERCM3RMRzZMMF9EeFVOcXpZYkFLbzhB?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics jumps as it confirms Nasdaq bid-price compliance after reverse split | XRTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQeDdlWEpmcG5BQ2poeTJhVUVQaE1aZjdkX0FHNFloa3hvclhseHNUWVU5QTJMc044aXI0c0psdXpueldGSWVKU3V6SHZuZ0xZSFZyYmJXeWNQUDhYMFFwYU1TeFJnaUlIckJXQWM5a3p4ckRXTmNRX3l5V1N5dzVTSkRhOE5MdmVlb1JqSXhQNUt4NDlvTlZIUVlJbGgySFBvR1VRWS1SR3N3anNKZU41bWJhVlN2cHRIbnJfMQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xortx Therapeutics (XRTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBGTFpfN1pBY205UndsQTFtNUZNa1RsOTRtVDctT2tYTWdySUZIeHZGZEhneVlkb1BzZUFGVW5QTjk3OXJ1MG9Iai1qQXdULUtNRm9n?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:10:48+00:00", "published_display": "25 Apr 2025 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc. (XRTX) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE5mMTBFNzVuR1pLc2JkLWxWWEw1ejJDWjZYYVh3aDlDel9ZVFBqbmYtTGZhamV4VE40RHRXa3BnN1lFV0t4LXZvSnI2cnpGWmNSZkRuSXpWbTNiTmdnWi1n?oc=5", "source_name": "CoinCodex", "published_at": "2023-03-16T22:52:22+00:00", "published_display": "16 Mar 2023 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for XORTX Therapeutics (XRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5zeUhmZjRqWGl3YzQwVk1WOUpxWUtrTk9zdmRaWDhVQnRrbGFCZFJMZUJ0Ry1fYUN2QW9vOGM5ZFlKMEUycm1xUUZFZmhJbC15NW5lTjh4bXBxN3FMWEpCOWlPVmN3c0dPQWotRTBTeU5pNjBmRlJaTw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-31T19:07:35+00:00", "published_display": "31 Aug 2022 19:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "XORTX Therapeutics (XRTX) Investor presentation Summary", "summary": "This article summarizes an investor presentation by XORTX Therapeutics (XRTX), highlighting its drug candidates XRx-026 for gout and XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XRx-026 targets a significant market opportunity with NDA submission planned for ", "url": "https://quartr.com/events/xortx-therapeutics-inc-xrtx-investor-presentation_F6YbmTrE", "source_name": "Quartr", "published_at": "2026-07-20T16:41:35", "published_display": "20 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Q4 2024 earnings summary", "summary": "XORTX Therapeutics (XRTX) reported an unqualified audit opinion for 2024, but with material uncertainty regarding its ability to continue as a going concern due to recurring operating losses and the need for additional financing. The company's cash decreased to $2.47M, and it rep", "url": "https://quartr.com/events/xortx-therapeutics-xrtx-q4-2024_F6YbyXRI", "source_name": "Quartr", "published_at": "2026-07-20T16:41:35", "published_display": "20 Jul 2026 16:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of XORTX Therapeutics, Inc. \u2013 LSX:A427MJ", "summary": "This article focuses on the \"Price to earnings forward\" financial metric for XORTX Therapeutics, Inc. (A427MJ) listed on the Lang & Schwarz Exchange, according to TradingView. The content provided is minimal, indicating no trades and a closed market. It also highlights the origin", "url": "https://www.tradingview.com/symbols/LSX-A427MJ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T19:10:04", "published_display": "13 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains Momentum - Money Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUVNPaUExZmtlN09GWlp1R0hLdGhWQktHR2hmN0N4RXYzX0ZiTUJQdURJcVRaZnpXeXJ4TFptNXhNclFnRHgtWE5KSHBHYUE0c2NockQ2TTlIZGtqbUpzUmhVZ3ZnNXhQRTJKeFJsdTdGXzhpeGFqUGpSYko3TUxPUmU0VUZVc054UUVVbTR1blZxOUp5NHFZMTFyMDl4UTI3ZjZUZmtJc2hEU2tTaVZsMDNn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T22:41:04+00:00", "published_display": "12 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum Builds - Descending Triangle", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNcmNUd0d6VUV1TWVETVlGQkw1ZGt2TlpKRXJzRzlMUndiRGk0a2JPRjQ3c085Q2E0V3AxM0M5dWR4VDJ0bUJHUkVSZUljaFh5NkFLVW1aMENxWGwybjZhZjlEX0RaaG1iSDB4aWVXN09FSzNhU29BZFFteTIzNWpqT1ZOU0ZrSGFPUFJjbHk4eGdteXQwYWhlVmJDanNhUEhRdjU3ODhB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T22:38:27+00:00", "published_display": "12 Jul 2026 22:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for XORTX Therapeutics Inc. (XRTX) stock. It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also includes general trading information an", "url": "https://timothysykes.com/quote/XRTX/", "source_name": "timothysykes.com", "published_at": "2026-07-09T10:39:56", "published_display": "09 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xortx Therapeutics updates investors on kidney disease focus", "summary": "Xortx Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for progressive kidney disease and conditions associated with elevated uric acid. The company's strategy centers on long-term growth through clinical development milestones rather tha", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xortx-therapeutics-updates-investors-on-kidney-disease-focus/69716072", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:53", "published_display": "07 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of XORTX Therapeutics, Inc. \u2013 TSXV:XRTX", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for XORTX Therapeutics, Inc. (TSXV:XRTX). It is a financial data page from TradingView, displaying stock information for XORTX Therapeutics within the Health Technology and Pharmaceuticals sector on the TSX Ven", "url": "https://www.tradingview.com/symbols/TSXV-XRTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T23:12:13", "published_display": "05 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News", "summary": "This article provides access to the stock options chain, quotes, and news for XORTX Therapeutics (XRTX). It serves as a financial data portal for investors interested in the company's stock performance and related market activities.", "url": "https://www.moomoo.com/stock/XRTX-US/options-chain?chain_id=Name1K9-3FXPhg.1kvafk0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FSOFI-US%2Ffinancials-key-indicators%22%7D", "source_name": "Moomoo", "published_at": "2026-07-05T21:41:33", "published_display": "05 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of XORTX Therapeutics, Inc. \u2013 TSXV:XRTX", "summary": "The article discusses the forward price-to-sales ratio for XORTX Therapeutics, Inc. (TSXV:XRTX). It also mentions that the stock market for XRTX is currently closed with no trades. The majority of the content consists of navigation links and policy information for the TradingView", "url": "https://www.tradingview.com/symbols/TSXV-XRTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T04:10:41", "published_display": "05 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of XORTX Therapeutics Inc (XRTX) focusing on its financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. However, it notes that key financial data such as total revenue, operating profit, and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:49", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for XORTX Therapeutics Inc (XRTX), detailing its current stock price, market cap, and daily performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet. The content i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:44", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "XORTX Therapeutics Inc (XRTX) has a \"Buy\" trend rating based on one analyst's assessment, with a target price of USD 14.00, representing a significant upside potential of +2943.48%. The article provides an overview of earnings forecasts, analyst ratings, and peer comparisons for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:13", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Institutional Confidence", "summary": "This article provides details on XORTX Therapeutics Inc (XRTX)'s institutional confidence, including its current stock price, market capitalization, and changes in institutional shareholdings. Several institutional investors and individuals are listed with their shareholdings and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:13", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of XORTX Therapeutics Inc (XRTX) including its current stock price, market capitalization, and historical dividend and stock split information. It notes that the company has not distributed any dividends in the past five years but has undergone s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:29", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides details on XORTX Therapeutics Inc (XRTX), including its market capitalization and recent stock performance. It notes that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also serves as a gene", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xrtx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:29", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]", "summary": "This document is a 6-K report filed by XORTX Therapeutics, indicating it is a report of a foreign private issuer under the Securities Exchange Act. The content consists solely of the word \"Document,\" suggesting it is a placeholder or a link to a separate document.", "url": "https://www.moomoo.com/news/notice/307528807/xortx-therapeutics-6-k-report-of-foreign-private-issuer-rules", "source_name": "Moomoo", "published_at": "2026-06-16T02:39:44", "published_display": "16 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-therapeutics-appoints-mika-grasso-132347043.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:23:47+00:00", "published_display": "15 Jun 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xortx Therapeutics Appoints Mika Grasso as Co-CEO; Provides Gout Drug Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-therapeutics-appoints-mika-grasso-131555980.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:15:55+00:00", "published_display": "15 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A 28-year-old co-CEO and XORTX's $700M gout push in the US", "summary": "XORTX Therapeutics has appointed Mika Grasso, 28, as co-CEO to oversee finance and public markets, coinciding with a corporate update detailing its strategic path for gout and kidney disease programs. The company is preparing an IND and planning a 505(b)(2) NDA submission for its", "url": "https://www.stocktitan.net/news/XRTX/xortx-provides-corporate-update-and-announces-appointment-of-mika-h6v6rkezpseq.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:40:14", "published_display": "15 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO", "summary": "XORTX Therapeutics is strategically refocusing on its lead gout drug candidate, XRx-026, and expanding its leadership team with the appointment of Mika Grasso as co-CEO for finance and public markets. The company plans to submit an IND and an NDA via the 505(b)(2) pathway, suppor", "url": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-3e4b6793b7b2.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:40:14", "published_display": "15 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO", "summary": "XORTX Therapeutics Inc. has provided a corporate update, refocusing on drug development programs and regulatory filings for its lead gout treatment, XRx-026. The company announced the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets, and is advanci", "url": "https://www.globenewswire.com/news-release/2026/06/15/3311671/0/en/xortx-provides-corporate-update-and-announces-appointment-of-mika-grasso-as-co-ceo.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing", "summary": "XORTX Therapeutics Inc. (TSE:XRTX) announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs, administrative burdens, and regulatory complexities. The company will maintain its Nasdaq listing, ensuring all shareholders can contin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XRTX-Q/pressreleases/2458260/xortx-to-voluntarily-delist-from-tsx-venture-exchange-maintain-nasdaq-listing/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T13:40:00", "published_display": "14 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange", "summary": "XORTX Therapeutics Inc. (NASDAQ: XRTX) has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs, optimize financing initiatives, and minimize regulatory complexity. The company determined that maintaining a dual listing was ", "url": "https://www.globenewswire.com/news-release/2026/06/12/3311334/0/en/xortx-announces-election-to-voluntary-delist-from-the-tsx-venture-exchange.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T12:10:19", "published_display": "13 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture", "summary": "XORTX Therapeutics has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs and administrative burdens associated with a dual listing. The company will maintain its listing on Nasdaq, where all shareholders will continue to ", "url": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-0e10adbeb0c3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:33", "published_display": "12 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX drops TSX Venture listing to reduce costs, focus on gout drug", "summary": "XORTX Therapeutics Inc. (NASDAQ:XRTX) has voluntarily decided to delist its common shares from the TSX Venture Exchange to reduce costs and streamline operations, according to a strategic review. The move is expected to cut exchange, legal, and accounting fees, optimize financing", "url": "https://www.stocktitan.net/news/XRTX/xortx-announces-election-to-voluntary-delist-from-the-tsx-venture-rsh5in5mrkqx.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:39:33", "published_display": "12 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XRTX - XORTX Therapeutics Inc Stock Price and Quote", "summary": "This article provides detailed stock information for XORTX Therapeutics Inc (XRTX), including its latest closing price, financial metrics, insider ownership, performance over various periods, and recent news releases. It covers aspects like market capitalization, sales, earnings ", "url": "https://finviz.com/stock?t=XRTX", "source_name": "Finviz", "published_at": "2026-06-03T20:40:07", "published_display": "03 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Edges Higher as Stock Holds Above Key Support - Schiff Line", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNeUJidHIzQ285TXBMOGdSUUdESWNiaE1EQlRaTGxITWdpSnhDNmtyaE1teFRsdndyYjF1UWcteWUzcVVudFNtMTUzelVDcU4weEJyZmw5MTNRSnBwM1Z2Vmdya3hydFQ1MUNwR1NjNUZmMHhJOE9iQXdYR0laQkdzNG5CNlNaUHFJMmFzMnRfS0RoMHpUUHU1VzNha0dWcHhTd1NPdXJjengtY3FMOERpLS1LWQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading Session - Factor Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUzEtQ25CaGNTQ0lqWEp0eFFaZ3QzQURmc0VqejlraEdyWjJicXI3eUU3WUI0UkdWN0ZKVnJvMG1HcG45bHlwTVBmcEVUblpsZlI3VjBiVDVycHZZV045dk0wdGJLanNJbzAxMTNGbGJDajhrN0FrOUhwQzZralRKWXYyOHhWc2hLTjNmbEh6M3RQX3N5dGpzTWpGeUV1bHlxRVNGRFB3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics (XRTX) Gains 1.27% as Shares Test Key Resistance Level - Overnight Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQUGp6NHB4SFM4cGVId3JKZ3RHVHpsR1B3TXplWDFaZ2czaGIzNUZYZENKWEtwT2pTb1BIaS05VWxTV1kwQ25CM1JkVGd5N3pjaV9OZmNFOWpBQ0xJMlBIX2tkVUZTUk5VTVdzYUQ4T1dCb2tjbEhQMDdHeWRiLTI3YU01alB0NVE5TEYyWHNNaVA2dU55dG9nX0p4Q0VEcmRXN1EzMG00RkdtZnpqcXFtWklYZFg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XRTX News | XORTX THERAPEUTICS INC (NASDAQ:XRTX)", "summary": "This article provides recent news and stock information for XORTX Therapeutics Inc. (NASDAQ: XRTX). It highlights the current stock price, after-hours trading, and recent press releases, including the closing and announcement of a US$5 million public offering.", "url": "https://www.chartmill.com/stock/quote/XRTX/news", "source_name": "ChartMill", "published_at": "2026-05-27T05:09:24", "published_display": "27 May 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Company Profile & Introduction", "summary": "This entry serves as a company profile and introduction for XORTX Therapeutics.", "url": "https://www.moomoo.com/stock/XRTX-US/company?chain_id=Name1K9-3FXPhg.1l0a440&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FNWLFF-US%2Ffinancials-income-statement%22%7D", "source_name": "Moomoo", "published_at": "2026-05-22T16:39:07", "published_display": "22 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Announces Closing of US$5 Million Public Offering", "summary": "XORTX Therapeutics Inc. has closed a public offering of common shares and pre-funded warrants, raising US$5 million. The company plans to use the net proceeds for working capital, general corporate purposes, and investor relations activities, including a US$2.5 million payment to", "url": "https://www.globenewswire.com/news-release/2026/05/19/3297319/0/en/xortx-announces-closing-of-us-5-million-public-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T01:39:57", "published_display": "20 May 2026 01:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Raises US$5 Million Via Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-therapeutics-raises-us-5-121501672.html", "source_name": "MT Newswires", "published_at": "2026-05-19T12:15:01+00:00", "published_display": "19 May 2026 12:15", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/e-f-hutton-co-serves-152000474.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T15:20:00+00:00", "published_display": "18 May 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9%", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/xortx-therapeutics-raising-us-5-181709580.html", "source_name": "MT Newswires", "published_at": "2026-05-14T18:17:09+00:00", "published_display": "14 May 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Announces US$5 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xortx-announces-us-5-million-110000771.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:00:00+00:00", "published_display": "14 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Meets Nasdaq Continued Listing Requirements", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQajJ3U21JU2xCbUNjZVhla20yeVZ2S0xMSF9aX1F3WWtSWmltZWw4ZEd6OFJ1OTBSTXB2blVwcEFXSUxQMUFEYUdtMW5sN084UU9OTDNBN1BUYW9mc0lpV1R3VjRwQWpKZF9jZk1tS1d4dWJpb3FpM3hkVU00Ni1wcW1iSlBNVG5wRUFKOERCM3RMRzZMMF9EeFVOcXpZYkFLbzhB?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics jumps as it confirms Nasdaq bid-price compliance after reverse split | XRTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQeDdlWEpmcG5BQ2poeTJhVUVQaE1aZjdkX0FHNFloa3hvclhseHNUWVU5QTJMc044aXI0c0psdXpueldGSWVKU3V6SHZuZ0xZSFZyYmJXeWNQUDhYMFFwYU1TeFJnaUlIckJXQWM5a3p4ckRXTmNRX3l5V1N5dzVTSkRhOE5MdmVlb1JqSXhQNUt4NDlvTlZIUVlJbGgySFBvR1VRWS1SR3N3anNKZU41bWJhVlN2cHRIbnJfMQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xortx Therapeutics (XRTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBGTFpfN1pBY205UndsQTFtNUZNa1RsOTRtVDctT2tYTWdySUZIeHZGZEhneVlkb1BzZUFGVW5QTjk3OXJ1MG9Iai1qQXdULUtNRm9n?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:10:48+00:00", "published_display": "25 Apr 2025 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XORTX Therapeutics Inc. (XRTX) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE5mMTBFNzVuR1pLc2JkLWxWWEw1ejJDWjZYYVh3aDlDel9ZVFBqbmYtTGZhamV4VE40RHRXa3BnN1lFV0t4LXZvSnI2cnpGWmNSZkRuSXpWbTNiTmdnWi1n?oc=5", "source_name": "CoinCodex", "published_at": "2023-03-16T22:52:22+00:00", "published_display": "16 Mar 2023 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for XORTX Therapeutics (XRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5zeUhmZjRqWGl3YzQwVk1WOUpxWUtrTk9zdmRaWDhVQnRrbGFCZFJMZUJ0Ry1fYUN2QW9vOGM5ZFlKMEUycm1xUUZFZmhJbC15NW5lTjh4bXBxN3FMWEpCOWlPVmN3c0dPQWotRTBTeU5pNjBmRlJaTw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-31T19:07:35+00:00", "published_display": "31 Aug 2022 19:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 51, "sentiment_summary": {"positive": 13, "negative": 4, "neutral": 34, "score": 53, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.01, "latest_week": "2026-07-17", "one_week_move": -7.6, "four_week_move": -3.8, "twelve_week_move": -33.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.083452, "market_dynamics_buy_signal": false, "relative_strength": -39.149617, "fair_value_gap": -76.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.9686, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.6% over one week, -3.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 6}, {"label": "dars.gov.et", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "Moomoo", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 15}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.6% over one week, -3.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "XORTX Therapeutics (XRTX) Investor presentation Summary"}], "updated_at": "2026-07-22T22:34:10.857820+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}